| pubmed-article:8053886 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8053886 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
| pubmed-article:8053886 | lifeskim:mentions | umls-concept:C0041178 | lld:lifeskim |
| pubmed-article:8053886 | lifeskim:mentions | umls-concept:C0004340 | lld:lifeskim |
| pubmed-article:8053886 | lifeskim:mentions | umls-concept:C0596545 | lld:lifeskim |
| pubmed-article:8053886 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:8053886 | lifeskim:mentions | umls-concept:C0238711 | lld:lifeskim |
| pubmed-article:8053886 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:8053886 | pubmed:dateCreated | 1994-9-8 | lld:pubmed |
| pubmed-article:8053886 | pubmed:abstractText | Sixty-five patients with high-risk trophoblast disease have been treated with the EMACO combination split regimen therapy in the 10 year period, 1981 to 1990. Four patients died but the remaining 61 (94%) remain free of disease up to 10 years later. Toxicity was manageable in most cases with minimal delay in treatment from myelosuppression. EMACO is a well tolerated regimen with a high cure rate in patients with high-risk gestational trophoblast disease (GTD). | lld:pubmed |
| pubmed-article:8053886 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8053886 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8053886 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8053886 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8053886 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8053886 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8053886 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8053886 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8053886 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8053886 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:8053886 | pubmed:issn | 0004-8666 | lld:pubmed |
| pubmed-article:8053886 | pubmed:author | pubmed-author:MurrayJJ | lld:pubmed |
| pubmed-article:8053886 | pubmed:author | pubmed-author:FriedlanderMM | lld:pubmed |
| pubmed-article:8053886 | pubmed:author | pubmed-author:QuinnMM | lld:pubmed |
| pubmed-article:8053886 | pubmed:author | pubmed-author:MarsdenDD | lld:pubmed |
| pubmed-article:8053886 | pubmed:author | pubmed-author:HammondII | lld:pubmed |
| pubmed-article:8053886 | pubmed:author | pubmed-author:JoblingTT | lld:pubmed |
| pubmed-article:8053886 | pubmed:author | pubmed-author:KholTT | lld:pubmed |
| pubmed-article:8053886 | pubmed:author | pubmed-author:SteigradSS | lld:pubmed |
| pubmed-article:8053886 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8053886 | pubmed:volume | 34 | lld:pubmed |
| pubmed-article:8053886 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8053886 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8053886 | pubmed:pagination | 90-2 | lld:pubmed |
| pubmed-article:8053886 | pubmed:dateRevised | 2009-11-11 | lld:pubmed |
| pubmed-article:8053886 | pubmed:meshHeading | pubmed-meshheading:8053886-... | lld:pubmed |
| pubmed-article:8053886 | pubmed:meshHeading | pubmed-meshheading:8053886-... | lld:pubmed |
| pubmed-article:8053886 | pubmed:meshHeading | pubmed-meshheading:8053886-... | lld:pubmed |
| pubmed-article:8053886 | pubmed:meshHeading | pubmed-meshheading:8053886-... | lld:pubmed |
| pubmed-article:8053886 | pubmed:meshHeading | pubmed-meshheading:8053886-... | lld:pubmed |
| pubmed-article:8053886 | pubmed:meshHeading | pubmed-meshheading:8053886-... | lld:pubmed |
| pubmed-article:8053886 | pubmed:meshHeading | pubmed-meshheading:8053886-... | lld:pubmed |
| pubmed-article:8053886 | pubmed:meshHeading | pubmed-meshheading:8053886-... | lld:pubmed |
| pubmed-article:8053886 | pubmed:meshHeading | pubmed-meshheading:8053886-... | lld:pubmed |
| pubmed-article:8053886 | pubmed:meshHeading | pubmed-meshheading:8053886-... | lld:pubmed |
| pubmed-article:8053886 | pubmed:meshHeading | pubmed-meshheading:8053886-... | lld:pubmed |
| pubmed-article:8053886 | pubmed:meshHeading | pubmed-meshheading:8053886-... | lld:pubmed |
| pubmed-article:8053886 | pubmed:meshHeading | pubmed-meshheading:8053886-... | lld:pubmed |
| pubmed-article:8053886 | pubmed:meshHeading | pubmed-meshheading:8053886-... | lld:pubmed |
| pubmed-article:8053886 | pubmed:meshHeading | pubmed-meshheading:8053886-... | lld:pubmed |
| pubmed-article:8053886 | pubmed:meshHeading | pubmed-meshheading:8053886-... | lld:pubmed |
| pubmed-article:8053886 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:8053886 | pubmed:articleTitle | EMACO in high risk gestational trophoblast disease--the Australian experience. Gestational Trophoblast Subcommittee, Clinical Oncological Society of Australia. | lld:pubmed |
| pubmed-article:8053886 | pubmed:affiliation | Royal Women's Hospital, Carlton, Victoria. | lld:pubmed |
| pubmed-article:8053886 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8053886 | pubmed:publicationType | Case Reports | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8053886 | lld:pubmed |
